Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REIMAGINE 1 trial of once-weekly CagriSema versus placebo in adults with type 2 diabetes inadequately controlled with diet and exercise
CTR20241583Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- May 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of cagrilintide, semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started May 2024; status: completed.
02
Drugs
cagrilintidesemaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20241583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241583.